Judge Rules in Louisiana v. FDA Case
OUR STATEMENT
Today, a judge from the Western District Court of Louisiana granted the Trump Administration’s request to stay State of Louisiana et al v Food and Drug Administration until the Food and Drug Administration conducts and finalizes yet another politically motivated review of mifepristone. As a result, access to mifepristone is unchanged across the country.
Dr. Jamila Perritt, ob/gyn in Washington DC and President & CEO at Physicians for Reproductive Health responds:
“Today’s decision to maintain access to mifepristone via telehealth access reaffirms what we’ve known to be true for years: medication abortion is safe, it’s effective, and its safety does not change whether dispensed in person or via telehealth care.
“Telehealth is a lifeline for thousands of patients across the United States. After Dobbs, over a quarter of patients who accessed abortion care did so thanks to the providers offering compassionate care via telehealth. Telehealth access to health care is meaningful for all of us. No matter the state, telehealth offers patients the ability to get the care they need whether it’s the most comfortable way to access care, or whether facing political, personal, or geographic barriers to an in-person clinic.
“People deserve access to the abortion care they need where they live and with the support they need. This truth is made more possible thanks to telehealth.
“We urge the Food and Drug Administration to issue the data and findings it has already collected time and time again to inform its guidance around mifepristone; the data shows mifepristone is a safe and effective medication as a part of the medication abortion regimen, and remains just as safe when dispensed to patients via telehealth.
“We see this effort by the state of Louisiana to ban mifepristone access via telehealth for what it is: a shoddy attempt to further limit people’s options to decide what to do with their bodies and their lives.”
The post Judge Rules in Louisiana v. FDA Case appeared first on Physicians for Reproductive Health.